article_snippet: The Joint Committee on Vaccination and Immunisation said approval was subject to a cost-effective price being agreed between the manufacturer and the Department of Health, with talks beginning in July 2014.
article_snippet: a cost-effective price being agreed between the manufacturer and the Department of Health being considered under negotiations is around £20 – a significant saving compared with GlaxoSmithKline's 'list price' of £75.
article_snippet: GPs are also paid a £7.50 fee for each dose administered.
article_snippet: Chris Head, chief executive of the Meningitis Research Foundation, said: 'These price negotiations have been ongoing since July 2014. '
highlights_snippet: But the NHS has failed to agree a price after nine months of negotiations .
  